Levetiracetam-induced diffuse interstitial lung disease.
The authors report the first case of levetiracetam-induced diffuse interstitial lung disease. The patient is a 9-year-old girl who was admitted to the pediatric intensive care unit for aspiration pneumonia. She has a history of epilepsy, cerebral palsy, mental retardation, asthma, and repeated hospitalizations for presumed aspiration pneumonia, which resolved with conventional medical treatment. She has been on low-dose levetiracetam for her epilepsy over the past 2 years, and the dosage was increased just prior to this admission. However, this time, with conventional treatment, the patient's aspiration pneumonia did not improve, which led to a lung biopsy. The biopsy demonstrated a diffuse interstitial process of relatively recent onset, with features consistent with diffuse lung disease. Levetiracetam was implicated in the pathogenesis of the interstitial pneumonitis. The patient improved clinically after the discontinuation of levetiracetam and with the treatment of steroids.
Newsome
Scott D
SD
Department of Neurology, Albany Medical Center, Albany, NY 12208, USA. newsoms@mail.amc.edu
Xue
Lanny Y
LY
Jennings
Timothy
T
Castaneda
Glenn Y
GY
D000927:Anticonvulsants / Q000009:adverse effects*; D002648:Child; D004827:Epilepsy / Q000188:drug therapy; D005260:Female; D006801:Humans; D000077287:Levetiracetam; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000473:pathology; D010889:Piracetam / Q000009:adverse effects / Q000031:analogs & derivatives*
D000927:Anticonvulsants; D000077287:Levetiracetam; D010889:Piracetam